− )-generating enzyme first identified in phagocytes that shows bactericidal activities. It has been reported that O 2 − is also produced in an NADPHdependent manner in non-phagocytes. In the last decade, non-phagocyte-type NADPH oxidases have been identified, and the catalytic subunit NOX family has been found to be composed of five homologs, NOX1 to NOX5, and two related enzymes, DUOX1 and DUOX2. These NOX proteins have distinct features in dependency on other components for maximal enzymatic activity, tissue distribution, expressional regulation, and physiological functions. This review summarized the distinct characteristics of NOX family proteins, especially focusing on their functions and mechanisms of their expressional regulation.
Introduction
Reactive oxygen species (ROS) including hydrogen peroxide (H 2 O 2 ), hydroxyl radical, singlet oxygen, peroxynitrite, and superoxide (O 2 − ) have been documented as intrinsic signaling molecules that modulate multiple cellular responses. ROS have both beneficial and detrimental properties. ROS exert bactericidal activities by oxidizing infected microorganisms. On the other hand, they are risk factors of cardiovascular diseases, causing lipid peroxidation and inactivation of the vasodilation factor nitric oxide (NO).
Major sources of O 2 − in the body are NADPH oxidases. They generate O 2 − from oxygen using NADPH as an electron donor. Studies on NADPH oxidases have been performed mainly in phagocytes such as neutrophils because mutations in the gene encoding the phagocyte NADPH oxidase were found in patients with chronic granulomatous disease (CGD) (1) . The phagocyte NADPH oxidase is composed of two membrane proteins gp91phox (cytochrome b558 heavy chain, later designated as NOX2) and p22phox; three cytosolic proteins, p67phox, p47phox, and p40phox; and a small GTPbinding protein Rac (Table 1 and Fig. 1A ). NOX2 is the catalytic subunit of this enzyme. Bacterial infection induces association and translocation to the phagosome membrane of the cytosolic components and gives rise to activation of this enzyme.
On the other hand, it has been reported that O 2 − is produced in an NADPH-dependent manner in nonphagocytes such as vascular smooth muscle cells (VSMC) or gastrointestinal epithelial cells. Because NOX2 is not expressed in these cells, the presence of non-phagocyte-type NOX2 homologs has been suggested. Identification of a NOX2 homolog, which is highly expressed in colon epithelial cells (CEC), was reported by Suh et al. in 1999 (2) and by Banfi et al. in 2000 (3) . This homolog was designated as NOX1. To date, five NOX isoforms (NOX1, NOX2, NOX3, NOX4, and NOX5) and two related enzymes, DUOX1 and DUOX2, were reported.
NOX enzymes have six transmembrane regions at the N-terminal half. In the third and fifth transmembrane domains, four heme-binding histidines are conserved. In the C-terminal cytosolic region, they have an FADbinding domain and an NADPH-binding domain. In addition to these domains, NOX5 has EF-hands, the Ca 2+ -binding domains, at the N-terminus. In addition to EF-hands, DUOX enzymes have a membrane-spanning region and a peroxidase-like domain at the N-terminus (Fig. 1B) .
NOX2

Activation mechanisms of NOX2 by cytosolic components
As mentioned above, NOX2 was first designated as gp91phox (cytochrome b558 heavy chain), the catalytic subunit of the phagocyte NADPH oxidase. The NOX2 gene was identified as a responsible gene for CGD (1) . NOX2/NADPH oxidase is composed of NOX2, p22phox, p67phox, p47phox, p40phox, and the small GTP-binding protein Rac. Activation mechanisms of NOX2/NADPH oxidase were well documented in other reviews (4, 5) . NOX2 and p22phox are associated at the plasma membrane and stabilize each other. p67phox, through its Cterminal Src homology 3 (SH3) domain, is associated with the C-terminal proline-rich region (PRR) of p47phox. p47phox has two SH3 domains necessary for its association with the C-terminal PRR of p22phox. In the resting state, the SH3 domains bind intramolecularly to the autoinhibitory region (AIR) in the C-terminal half, interrupting binding to p22phox. The N-terminal phagocyte oxidase (PX) domain of p47phox is necessary for binding to membrane phosphoinositides. Another cytoplasmic component p40phox is associated with p67phox via mutual Phox/Bem1p (PB1) domains. Phagocytosis of bacteria or stimulation with phorbol ester (TPA) induces phosphorylation and conformational change in p47phox, enabling its binding to p22phox. Rac is associated with GDP nucleotides dissociation inhibitor for Rho (RhoGDI) in the cytosol. With stimulation, Rac translocates to the membrane independently of p47phox and p67phox. GTP-bound Rac interacts with the N-terminal region of p67phox containing four tetratricopeptide repeat (TPR) motifs. Thus, translocation of cytosolic components to the phagosome membrane and association to the membrane subunits are achieved, leading to the activation of this enzyme.
Transcriptional regulation of NOX2
In addition to the regulation of the enzymatic activity by cytosolic components, the expression level of NOX2 is known regulated at the level of transcription. Point mutations at −57, −55, −53, and −52 bp of the NOX2 promoter have been detected in patients with CGD (6, 7). The transcription of NOX2 is restricted to myeloid cells differentiated beyond the promyelocyte stage. Interferon (IFN)-γ and lipopolysaccharide (LPS) were shown to increase the expression level of NOX2 in human monocyte-derived macrophages and neutrophils (8) . TPA or retinoic acid / dimethylformamide (DMF) was also reported to induce NOX2 expression in myeloid cells (9) . A number of DNA-binding proteins were shown to interact with the NOX2 promoter region, including BID (binding increased during differentiation), IFN regulatory factor (IRF)-1, IRF-2, the CCAAT box binding protein CP1, and the transcriptional repressor CDP (CCAAT displacement protein) (9 -13). Voo and Skalnik reported that Elf-1 and PU.1, both of which are Ets family transcription factors highly expressed in myeloid cells, bound to the NOX2 promoter (14) . Protein kinase C (PKC)-dependent phosphorylation of PU.1 was reported to be involved in IFN-γ-induced expression of NOX2 in human monocytes (15) . Bei et al., on the other hand, reported that the transcription of NOX2 during myeloid differentiation was activated by HoxA9 but repressed by HoxA10, both of which are homeodomain transcription factors (16) . They also found HoxA10-dependent transcriptional repression of p67phox (17) . Tyrosine phosphorylation by Janus tyrosine kinase 2 (JAK2), which is activated by stimulation with IFN-γ, was shown to decrease DNAbinding activity of HoxA10 and repression of NOX2 transcription (18) . On the other hand, activation of the protein-tyrosine phosphatase SHP-2 was shown to increase HoxA10-induced transcriptional repression of NOX2 and p67phox (19) . Yang et al. reported that GATA-1 was an activator and GATA-2 was a relative competitive inhibitor of GATA-1 in the eosinophil-specific expression of NOX2 (20) . NF-κB-dependent transcription of NOX2 was also reported, suggesting the possibility of a positive feedback loop in which NF-κB activation by oxidative stress leads to a further oxidative burst via NOX2/NADPH oxidase (21).
Deficiency of NOX2/NADPH oxidase
In CGD patients, phagocytes cannot generate O 2 − and lack bactericidal activity because of the defects in NOX2/ NADPH oxidase. This leads to the formation of granulomas in the lung, liver, lymph nodes, and gastrointestinal, urinary, and genital tracts.
Bendall et al. reported that NOX2/NADPH oxidase is involved in angiotensin (Ang) II-induced cardiac hypertrophy. Ang II significantly increased heart/body weight ratio, atrial natriuretic factor, and β-myosin heavy chain mRNA expression, myocyte area, and cardiac collagen content in wild-type but not in NOX2-deficient mice (22 3. NOX1
Identification of NOX1
NOX1 was originally isolated from CEC (2, 3) . It is also expressed in VSMC. Its expression is induced by vasoactive factors such as Ang II and platelet-derived growth factor (PDGF) and has been thought to be involved in proliferation and hypertrophy of VSMC (2, 24) . Expression of NOX1 was also reported in macrophages (25) and mast cells (26) . In these cells, NOX1 was suggested to be involved in foam cell formation and interleukin (IL)-1β-induced IL-8 secretion contributing to angiogenesis, respectively.
Like NOX2, NOX1 requires other components for its enzymatic activity. It was reported that p22phox, p67phox, p47phox, and Rac1 could compose NOX1/ NADPH oxidase (27, 28) . In addition, the p67phox homolog NOXA1 (NOX activator 1) and the p47phox homolog NOXO1 (NOX organizer 1) were identified. Unlike p67phox and p47phox, NOXA1 and NOXO1 were shown to be constitutively associated with NOX1 and p22phox, respectively (29 -31) . Subcellular localization of NOX1 to caveola or early endosomes was suggested (32, 33).
Transcriptional regulation of NOX1 in colon epithelial cells
The expression level of NOX1 is very high in the colon compared to other organs (2, 3). The human NOX1 gene is located on Xq22, and the mRNA is encoded by 13 exons. The initiation codon exists in the first exon. Several groups reported the mechanisms of transcriptional regulation of NOX1 in the colon. Brewer et al. reported that the transcription initiation site of the human NOX1 gene was 221 bases upstream of the initiation codon. In addition, they identified the GATA binding site at −135/−130 to be essential for the basal transcriptional activity using a human colon epithelial cell line Caco-2 (34). Valente et al. reported that the four regions at −201/−181, −177/−157, −149/−124, and −107/−88, to which GATA-4/5/6 could bind, are essential for the basal transcriptional activity in Caco-2 cells and that Cdx1/2 and HNF-1α could bind to −177/−157 and −149/−124, respectively (35) . The expression pattern of NOX1, which is highly expressed in the lower part of the large intestine, coincides with those of GATA-6, HNF-1α, and Cdx1. Therefore, these transcription factors may contribute to the expression of NOX1 in the colon. Involvement of GATA-6 in the NOX1 expression in Caco-2 cells was also reported by Adachi et al. Up-regulation of NOX1 by oncogenic Ras was shown to be mediated by MEK-ERK-dependent phosphorylation of GATA-6 (36). On the other hand, Kuwano et al. found that the expression of NOX1 is induced in the human colon epithelial cell line T84 stimulated with IFN-γ. The γ-activated sequence (GAS) at −3818/−3810 was essential for this induction, and phosphorylated STAT1 could bind to this sequence by stimulation with IFN-γ (37). They also reported the mechanism of expressional regulation of NOXO1 in colon epithelial cells. Although IL-1β, flagellin, IFN-γ, and tumor necrosis factor (TNF)-α similarly induced NOX1 expression in T84 cells, only TNF-α fully induced NOXO1 expression. They identified three putative binding sites for Sp1 and an AP-1 binding site of the human NOXO1 promoter as crucial elements for the TNF-α-dependent expression in the colon (38) . NOX1/NADPH oxidase in the colon was suggested to be involved in cell proliferation and post-mitotic differentiation by controlling the balance between goblet and absorptive cell types (39).
Phenotype modulation of VSMC and novel NOX1 transcripts
Although the expression level of NOX1 in VSMC is increased by stimulation with Ang II, PDGF, prostaglandin (PG) F 2α , aldosterone/high salt, serum, or TPA, the level is extremely low compared to that in CEC (24, 40, 41) . Therefore we thought that the mechanism of gene expression of NOX1 is fundamentally different in VSMC and CEC and at first analyzed the 5'-end of the NOX1 mRNA in VSMC (42). 5'-RACE identified cDNAs with longer 5'-ends from a mouse VSMC line, P53LMACO1, than that from the cecum. Sequence analysis revealed the first exon of the cecum cDNA contained the start codon like the human NOX1 mRNA. On the other hand, two novel cDNAs with additional exons at 5'-end were isolated from P53LMACO1 cells. Therefore we named the exon containing the start codon as exon 1a and additional 5'-exons as exons 1b -1f, respectively, and three kinds of mRNAs as a-type, c-type, and f-type by their 5'-exons, respectively (Fig. 2) . The c-type and f-type contained exon 1b, and ATG in this exon was used as the start codon, making the N terminus 28-residues longer than that of the a-type. The a-type was expressed not only in the cecum and a colon epithelial cell line MCE301 but also in the intact mouse aorta. On the other hand, the ctype was not expressed in the intact aorta, but its expression was induced by wire injury or Ang II administration or by culturing aortic VSMC in the presence of serum. Because the expression pattern of the c-type agreed with those of markers of phenotypic modulation of VSMC from the differentiated (constrictive) form to the dedifferentiated (proliferative) form, expression of the c-type NOX1 might be related to dedifferentiation of VSMC (42).
Mechanisms of NOX1 induction by vasoactive factors
PGF 2α , one of the primary prostanoids generated in the vascular tissue, was known to cause hypertrophy of VSMC. We found that this is mediated by O 2 − generated by induced NOX1 (40) . We next examined signaling pathways involved in the vasoactive factor-induced expression of NOX1 in VSMC.
First, we found diphenyleneiodonium (DPI), an inhibitor of flavoproteins including NADPH oxidase itself, almost completely suppressed induction of NOX1 mRNA by PGF 2α or PDGF in a rat VSMC line, A7r5. Exploration into the site of action for DPI using various inhibitors suggested involvement of mitochondrial oxidative phosphorylation in PGF 2α -or PDGF-induced increase in NOX1 mRNA. In a luciferase reporter assay, activation of the cAMP response element (CRE)-dependent gene transcription by PGF 2α was attenuated by oligomycin, an inhibitor of mitochondrial FoF1-ATPase. Oligomycin and other mitochondrial inhibitors also suppressed PGF 2α -induced phosphorylation of activating transcription factor (ATF)-1, a transcription factor of the CREB/ ATF family. Silencing of the ATF-1 gene by RNA interference significantly reduced the induction of NOX1 by PGF 2α or PDGF, while overexpression of ATF-1 recovered NOX1 induction suppressed by oligomycin. Thus, ATF-1 was shown to play a pivotal role in up-regulation of NOX1 in rat VSMC (43) .
We next found that PGF 2α enhanced the phosphorylation of the epidermal growth factor (EGF) receptor, and a selective inhibitor of EGF receptor kinase, tyrphostin AG1478, significantly suppressed PGF 2α -induced NOX1 expression in A7r5 cells. AG1478 also blunted the PGF 2α -induced phosphorylation of ERK1/2 and Akt. PI3 kinase inhibitors not only reduced PGF 2α -induced NOX1 expression, but also suppressed the phosphorylation of ATF-1. Accordingly, the transactivation of the EGF receptor and the activation of ERK1/2, PI3 kinase, and ATF-1 were shown to constitute the signaling pathways involved in the up-regulation of NOX1 (44) .
As the receptor for PGF 2α is known to activate PKC, involvement of PKC in up-regulation of NOX1 expression was investigated in A7r5 cells. GF109203x, a nonselective inhibitor of PKC, dose dependently suppressed the induction of NOX1 mRNA by PGF 2α . Among isoform-selective inhibitors, an inhibitor of PKCδ, rottlerin, significantly attenuated the PGF 2α -induced increase in NOX1 mRNA. Gene silencing of PKCδ by RNA interference significantly suppressed the PGF 2α -induced increase in NOX1 mRNA as well as phosphorylation of the EGF receptor, ERK1/2, and ATF-1. Silencing of the PKCδ gene also attenuated the PDGF-induced increase in NOX1 mRNA and transactivation of the EGF receptor. Thus, PKCδ was shown to mediate the transactivation of the EGF receptor elicited not only by PGF 2α , but also by PDGF, and the subsequent activation of ERK1/2 and ATF-1 was shown to lead to up-regulation of NOX1 expression (45) . To clarify the mechanisms of transcriptional regulation of NOX1 by vasoactive factors, we analyzed the 5'-end of the rat NOX1 mRNA isolated from cultured VSMC and the rat VSMC line A7r5. The rat NOX1 mRNA expressed in VSMC had an exon at the 5'-end homologous to exon 1c of the mouse NOX1. However, the counterpart of exon 1b was not found and the additional N-terminal peptide was not encoded. Reporter assays revealed that the binding site of myocyte enhancer factor 2 (MEF2) at −139/−130 was essential for the NOX1 induction by PGF 2α . Stimulation of A7r5 cells with PGF 2α increased binding of MEF2 to this sequence. Among four subtypes of MEF2, the expression level of MEF2B was extremely low, but was elevated by stimulation with PGF 2α or PDGF. RNA interference against MEF2B suppressed the induction of NOX1 by PGF 2α or PDGF. In addition, RNA interference against ATF-1 suppressed the induction of MEF2B by PGF 2α or PDGF. Thus, the induction of NOX1 in VSMC was found to be mediated by induction of MEF2B dependent on the activation of ATF-1 (46) .
We also identified an AP-1 binding site at −98/−92 essential for NOX1 expression in rat VSMC. PGF 2α and PDGF augmented the binding of JunB to this sequence, and an inhibitor of MAPK/ERK kinase suppressed the expression of JunB induced by PGF 2α or PDGF (47). Thus, not only the ATF-1-MEF2B pathway but also the ERK1/2-JunB pathway seems to regulate the inducible expression of NOX1 in VSMC.
Transcriptional regulation of NOX1 by NF-κB and activation of NF-κB by NOX1-derived O 2
−
NOX1 was reported to be expressed in mouse macrophages (25) . Stimulation with a TLR4 agonist LPS induced the expression of NOX1, and generated O 2 − was thought to be involved in form cell formation. The NOX1 mRNA species expressed in the mouse macrophage was the a-type. The induction was mediated by NF-κB, and a NF-κB binding site was found at −91/−82 of the mouse a-type NOX1 promoter (25) . Induction of NOX1 by LPS was also reported in gastric mucosal cells (27) . Thus, NF-κB might be a crucial transcription factor for the inducible expression of NOX1 in various cell types. Kim et al., on the other hand, reported that NOX1-derived O 2 − is involved in IL-1β-induced activation of NF-κB and transcriptional activation of the IL-8 gene in mast cells. IL-1β was shown to induce NOX1 expression via leukotriene (LT) B 4 -BLT2 receptor signaling (26) . Thus, there seems to be a positive feedback loop in which NF-κB activation by NOX1-derived O 2 − leads to further O 2 − production through induction of NOX1.
Physiological functions of NOX1/NADPH oxidase
We established NOX1 gene-disrupted mice and found a pivotal role for NOX1-derived ROS in the pressor response to Ang II (48) . No difference in the baseline blood pressure was observed between wild-type and NOX1-deficient mice. Infusion of Ang II induced a significant increase in mean blood pressure, accompanied by augmented expression of NOX1 mRNA and O 2 − production in the aorta of wild-type mice, whereas the elevation in blood pressure and production of O 2 − were significantly blunted in NOX1-deficient mice. Administration of a NO synthase inhibitor to wild-type mice did not affect the Ang II-mediated increase in blood pressure, but it abolished the suppressed pressor response to Ang II in NOX1-deficient mice. Endothelium-dependent relaxation and the level of cGMP in the isolated aorta were preserved in NOX1-deficient mice infused with Ang II. Thus, ROS derived from NOX1/NADPH oxidase was suggested to play a pivotal role in the pressor response to Ang II by reducing the bioavailability of NO.
We also reported the involvement of NOX1 in inflammatory pain. In mice lacking NOX1, thermal and mechanical hyperalgesia was significantly attenuated, whereas no change in nociceptive responses to heat or mechanical stimuli was observed. In dorsal root ganglia (DRG) neurons of wild-type mice, pretreatment with bradykinin, serotonin, or TPA augmented the capsaicininduced calcium increase, whereas this increase was significantly attenuated in DRG neurons of NOX1-deficient mice. Concomitantly, TPA-induced translocation of PKCε was markedly perturbed in NOX1-deficient or wild-type DRG neurons treated with ROS-scavenging agents. In cells transfected with tagged PKCε, H 2 O 2 induced translocation and a reduction in free sulfhydryls of full-length PKCε but not of the deletion mutant lacking the C1A domain. Thus, NOX1-derived O 2 − was suggested to accelerate the translocation of PKCε in DRG neurons, thereby enhancing the TRPV1-channel activity and the sensitivity to painful stimuli (49) .
Coant et al. reported that NOX1 modulates Wnt and Notch1 signaling to control the fate of proliferative progenitor cells in the colon. NOX1-deficient mice revealed a massive conversion of progenitor cells into post-mitotic goblet cells at the cost of colonocytes due to the concerted repression of PI3 kinase / Akt / Wnt / β-catenin and Notch1 signaling. This conversion correlated with the redox-dependent activation of the phosphatase PTEN causing the inactivation of the Wnt pathway effector β-catenin and with the down-regulation of Notch1 signaling that provokes derepression of Math1 (mouse atonal homolog 1) expression. Thus, NOX1 was suggested to control the balance between goblet and absorptive cell types in the colon by coordinately modulating PI3 kinase / Akt / Wnt / β-catenin and Notch1 signaling (39).
NOX3
The NOX3 gene was identified in the otoconia-deficient head tilt mice. In these mice, an allelic series of mutations in the otoconia-deficient head tilt (het) locus was found, causing a null mutation or point mutations in the NADPH binding site of NOX3 (50) . Thus, NOX3 is essential for gravity perception.
The expression of NOX3 is almost restricted to the inner ear. In situ hybridization demonstrated that NOX3 mRNA was expressed in the vestibular and cochlear sensory epithelia and to the spiral ganglions (51) . To date there are no reports on mechanisms of the inner earspecific expression of NOX3.
Importance of p22phox for the activity of NOX3 was reported, although organizers (p47phox or NOXO1), activators (p67phox or NOXA1), and Rac1 can enhance its activity (28, 51 -53) .
Kawahara et al. analyzed molecular evolution of NOX enzymes and revealed that NOX3 appeared late in evolution, corresponding to the permanent transition of vertebrates from water to land. Although fish and amphibians have otoconia, they do not have the NOX3 gene, suggesting a unique function of NOX3 in land vertebrates (54) .
Involvement of NOX3 in cisplatin-induced hearing loss was suggested. Mukherjea et al. reported that knockdown of NOX3 using short interfering (si) RNA abrogated cisplatin ototoxicity, as evidenced by protection of outer hair cells from damage and reduced threshold shifts in auditory brainstem responses in the rat. Transtympanic NOX3 siRNA reduced the expression of TRPV1 channel and kidney injury molecule-1 (KIM-1), biomarkers of cochlear damage. Also, transtympanic NOX3 siRNA reduced the expression of Bax, abolished the decrease in expression of Bcl2, and reduced apoptosis induced by cisplatin in the cochlea (55) . Thus, selective inhibitors of NOX3, of which expression is almost restricted to the inner ear, would be useful for preventing cisplatin ototoxicity in cancer patients.
NOX4
Identification of NOX4
NOX4 was first identified as "renal NOX" and then found to be expressed in various tissues (56 -58) . It was reported that NOX4 requires only p22phox to exert its enzymatic activity. NOX4 was shown to generate H 2 O 2 , rather than O 2 − , constitutively without other cytosolic components. Recently, it was reported that the C-terminal half (dehydrogenase domain) of NOX4/NOX2 determines its dependency on the cytosolic components for its activation (59, 60) . Another report demonstrated that the activity of NOX4 is determined by mRNA levels (61).
Thus, the expression level of NOX4 seems to lead directly to its enzymatic activity. Recently, polymerase (DNA-directed) delta-interacting protein 2 (Poldip2) was reported to interact with p22phox and enhance the activity of NOX4/NADPH oxidase (62) . Subcellular localization of NOX4 was demonstrated in focal adhesions, stress fibers, and nucleus of VSMC (62); perinuclear region of pulmonary arterial smooth muscle cells (PASMC) (63) ; endoplasmic reticulum (ER) in exogenously transfected cells (59) ; and mitochondria of mesangial cells and cardiomyocytes (64, 65).
Regulation of NOX4 expression
In contrast to NOX1, of which expression is induced by various bioactive factors in specific cell types, NOX4 is constitutively expressed in various cell types. Ubiquitous expression of NOX4 suggests it as a housekeeping gene. Indeed, the promoter region of the NOX4 gene contains many G or C bases, characteristics of housekeeping genes. Zhang et al. reported that E2F1 transcription factor is involved in the expression of rodents NOX4 in VSMC (66) .
On the other hand, inducible expression of NOX4 was also reported. Hypoxia has been reported to induce NOX4 expression in PASMC (63, 67) . Transforming growth factor (TGF)-β has also been known to induce the expression of NOX4 in various cell types (68 -71) . Cannabidiol, a nonpsychoactive cannabinoid, was reported to induce the expression of NOX4 and p22phox in human leukemia cells and their apoptosis. This effect was mediated by cannabinoid receptor 2 (CB2) (72). 7-Ketocholesterol, a major oxysterol contained in oxidized lowdensity lipoprotein, was reported to induce the expression of NOX4 in human aortic smooth muscle cells. This induction was mediated by IRE-1 (an ER-membrane kinase), Jun-N-terminal kinase (JNK), and AP-1. NOX4 was shown to induce ER stress and apoptosis. Thus, NOX4 was suggested to be involved in oxysterol-induced SMC death in the pathogenesis of atherosclerosis (73) . Ursolic acid, an active constituent of natural herbs, on the other hand, was reported to suppress the expression of NOX4 in endothelial cells. These natural compounds might exert their beneficial effects by decreasing NOX4 expression that leads to the increase in bioactive NO (74).
Induction of NOX4 expression by hypoxia
NADPH oxidases have been suggested to serve as oxygen sensors in the lung. Chronic hypoxia was known to induce vascular remodeling with medial hypertrophy leading to the development of pulmonary hypertension. Mittal et al. reported that NOX4 is expressed in the media of small pulmonary arteries and the expression level was increased by chronic exposure of mice to hypoxia. NOX4 induction was also observed in isolated PASMC after exposure to hypoxia. Also in lungs from patients with idiopathic pulmonary arterial hypertension, the level of NOX4 expression was up-regulated. Treatment of PASMC with an anti-NOX4 siRNA reduced PASMC proliferation (63) . Diebold et al. found a putative hypoxia responsive element in the human NOX4 promoter and demonstrated that this sequence is indispensable for the binding of hypoxia-inducible factor-1α (HIF-1α). RNA interference against HIF-1α suppressed hypoxia-induced expression of NOX4 (67) . Thus, NOX4 is a target gene of HIF-1α under the hypoxic condition, and NOX4 induced by hypoxia might be involved in the pathogenesis of various cardiovascular diseases through vascular remodeling.
Induction of NOX4 expression by TGF-β and its involvement in fibrosis
The expression of NOX4 has been reported to be induced by TGF-β in cardiac fibroblasts, smooth muscle cells in the pulmonary artery and airway, and hepatocytes (68 -71) . The induction was observed in Hep3B cells but not in HepG2 cells, both of which are human hepatocellular carcinoma cell lines (71) . Treatment with PD98059 recovered the reactivity of HepG2 cells to TGF-β, suggesting that the MEK/ERK pathway is involved in the suppression of NOX4 expression (75) .
Hecker et al. reported a role of NOX4 in tissue repair functions of myofibroblasts and fibrogenesis. TGF-β1 induced NOX4 expression in lung mesenchymal cells via Smad3, a receptor-regulated protein that modulates gene transcription. NOX4-derived H 2 O 2 was required for TGF-β1-induced myofibroblast differentiation, extracellular matrix production, and contractility. NOX4 was up-regulated in lungs of mice subjected to bleomycin-or hapten-induced injury and in cases of human idiopathic pulmonary fibrosis (IPF). RNA interference against NOX4 abrogated fibrogenesis in two murine models of lung injury. Thus, selective inhibitors of NOX4 would be useful for treatment of fibrotic disorders, if appropriate drug delivery systems were established for NOX4 ubiquitously expressed in the body (76).
Two aspects of NOX4-derived ROS and involvement in renal and cardiac pathogenesis
The functions of NOX4 are somewhat controversial. In some cell types, NOX4 acts as a regulator of proliferation, hypertrophy, or cell survival (63, 69, 70, 77, 78) . In other cell types, however, it acts as a regulator of apoptosis or differentiation (65, 71 -73, 75, 79) . The reason for these discrepancies has not been determined. Analyses using NOX4-knockout mice might clarify the physiological functions of NOX4.
Besides lung fibrogenesis, NOX4 seems to be involved in the pathogenesis of renal and cardiac diseases. Increased expression of NOX4 in diabetic kidney was reported, and its involvement in glomerular hypertrophy and fibronectin expression, features of diabetic nephropathy, was suggested (64, 80) . Ago et al. reported that the expression of NOX4 was increased in the heart in response to hypertrophic stimuli or aging. They established cardiomyocyte-specific NOX4 transgenic mice and found left ventricular dysfunction with aging. Overexpression of NOX4 in cultured cardiomyocytes induced apoptosis, but not hypertrophy, through oxidation of mitochondrial proteins (65) . Thus, NOX4 might be a molecular target for the treatment of various cardiovascular diseases.
NOX5
NOX5 was identified as a Ca 2+ -dependent NADPH oxidase (81) . It has four EF-hands, the Ca 2+ -binding domains, at the N-terminus. According to the evolutional analyses by Kawahara et al., Ca 2+ -regulated, EF-handcontaining NOXes appeared very early during the evolution of eukaryotes (54) .
Unlike other NOX proteins, NOX5 does not require other components for its activation. Therefore, its activation is dependent on Ca 2+ levels (82). Kawahara et al. reported that phosphatidylinositol (4,5)-bisphosphate [PtdIns(4,5)P 2 ] plays a key role in the translocation of NOX5 to the plasma membrane. The polybasic region between the fourth EF-hand and the first transmembrane region was shown to bind PtdIns(4,5)P 2 and be essential for membrane localization of NOX5 (83) . El Jamali et al., on the other hand, reported that H 2 O 2 induced O 2 -production in K562 cells expressing NOX5. This activation was mediated by Ca 2+ -dependent membrane translocation of c-Abl non-receptor tyrosine kinase, and association of NOX5 with c-Abl was suggested (84) .
NOX5 was found to be expressed in the testis, spleen, lymph nodes, and VSMC (81) . Analyses using genedisrupted mice are impossible because the NOX5 gene is missing in rodents. Involvement of NOX5 in PDGF-induced proliferation of VSMC (85) and the regulation of growth and apoptosis of prostate cancer cells (86) has been suggested. Expression of NOX5 was also demonstrated in hairy cells (mature malignant B cells), but not in circulating normal B cells (87) . NOX5-derived oxidants were shown to inhibit SHP-1 phosphatase, suggesting that NOX5 is involved in the constitutive phosphorylation signals in hairy cells (87) . Overexpression of NOX5 in Barrett's esophageal adenocarcinoma was also reported and its involvement in carcinogenesis was sug-gested. Platelet-activating factor (PAF) was shown to induce NOX5 expression in esophageal adenocarcinoma cells, and this induction was shown to be mediated by the binding of STAT5 to an element in the NOX5 promoter (88).
DUOX1 and DUOX2
DUOX1 and DUOX2 were identified as H 2 O 2 -producing enzymes in thyroid gland (89, 90) . The structure of DUOX is composed of the NOX-like region at the Cterminal half, two EF-hands, a membrane-spanning region, and a peroxidase-like domain at the N-terminus (Fig. 1B) . Therefore they were designated as a dual-oxidase, DUOX. DUOX-derived H 2 O 2 is essential for the synthesis of thyroid hormones by thyroid peroxidase. Mutations in the DUOX2 gene were reported in congenital hypothyroidism (91, 92) .
DUOX does not require other components of NADPH oxidase for its activity. However, DUOX maturation factors called DUOXA1 and DUOXA2 were identified as transmembrane proteins essential for ER-to-Golgi transition, maturation, and targeting to the plasma membrane of DUOX1 and DUOX2, respectively, as functional complexes (93, 94) . DUOXA1 was originally identified as numb-interacting protein 1 (NIP1). DUOXA1 and DUOXA2 genes were found arranged head-to-head to and co-expressed with DUOX1 and DUOX2 genes, respectively. A mutation in the DUOXA2 gene was also reported in congenital hypothyroidism (95) . Rigutto et al. reported differential activation of DUOX1 and DUOX2 by protein kinases. DUOX1 but not DUOX2 activity was stimulated by forskolin via protein kinase A-mediated DUOX1 phosphorylation on serine 955. In contrast, TPA induced DUOX2 phosphorylation via PKC activation (96) .
Both DUOX1 and DUOX2 were highly expressed in the thyroid gland. DUOX1 is also expressed in the airway epithelia, placenta, prostate, testis, pancreas, and heart (97, 98) . DUOX2 is expressed in epithelial cells in salivary excretory ducts and rectal glands (98, 99) . Lactoperoxidase (LPO), an enzyme with antimicrobial properties, was shown to be present in airway secretions and saliva, suggesting that DUOX enzymes play essential roles in host defense by supplying H 2 O 2 to LPO (98). Harper et al. reported that the expression of DUOX1 in the airway epithelia was increased by treatment with the Th2 cytokines IL-4 and IL-13, whereas DUOX2 expression was highly induced following treatment with the Th1 cytokine IFN-γ. DUOX2 expression was also elevated by polyinosine-polycytidylic acid and rhinovirus infection (100) . Differential regulation of DUOX1 and DUOX2 by Th1 and Th2 cytokines might be important for host defense and inflammation. Luxen et al. reported that the expression of DUOX1 and DUOX2 is often suppressed in lung cancer cells by hypermethylation of the CpG-rich promoter regions in both DUOX genes (101).
Species differences in the transcriptional regulation of NOX
In the analyses of the transcriptional regulation, human cell lines like Hela are often used not only for human genes but also for rodent genes. Such analyses are impossible unless the mechanisms of transcriptional regulation are conserved among different species. We found that the promoter activity of the human NOX1 gene was very high in human Caco-2 cells but low in mouse MCE301 cells, and the activity of the mouse a-type promoter was high in MCE301 cells but low in Caco-2 cells. In addition, the region reported to be essential for transcription of the human NOX1 mRNA was not necessary for transcription of the mouse a-type mRNA (42) . For the expression in VSMC, even though the MEF2 binding site was conserved in the mouse gene, the mouse c-type promoter did not show PGF 2α -dependent transcriptional activity in rat A7r5 cells. Furthermore, although a sequence homologous to rodent exon 1c was found in the human gene, it did not seem to encode an exon. In fact, c-type-like cDNA has not been isolated from human VSMC (M. Katsuyama et al., unpublished data). Thus, the transcription of NOX1 seems to be species-specific both in CEC and VSMC. As for NOX4, Zhang et al. reported that E2F1 transcription factor is involved in the expression of rodents NOX4 in VSMC (66) . The binding site of E2F1 was, however, not conserved in the human NOX4 gene. Furthermore, another isoform, NOX5, is expressed in human VSMC, but it is not encoded by rodent genes (54, 81) . Thus, NOX enzymes have species specificities in their expression. Such species differences should be considered for the development of drugs targeted at NOX/NADPH oxidases.
